SCHEMBL4645309

SCHEMBL4645309

CC(=O)Oc1ccc2c(c1OC(C)=O)C(=O)c1ccccc1C2=O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.58
NPC1 O15118 2/20 0.58
RAB9A P51151 2/20 0.58
TTR P02766 2/20 0.56
MAPT P10636 8/20 0.53
MEN1 O00255 5/20 0.53
KMT2A Q03164 5/20 0.53
ELANE P08246 2/20 0.51
ALDH1A1 P00352 6/20 0.47
MAPK1 P28482 6/20 0.47
KDM4E B2RXH2 4/20 0.47
ADORA2A P29274 3/20 0.47
LMNA P02545 3/20 0.47
USP2 O75604 2/20 0.47
ADORA3 P0DMS8 2/20 0.47
ADORA1 P30542 2/20 0.47
HPGD P15428 2/20 0.47
ABCC4 O15439 1/20 0.47
TP53 P04637 1/20 0.47
HSP90AA1 P07900 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8821546 0.86 ELANE (0.52) SMN1; SMN2NPC1RAB9ATTRMAPT
SCHEMBL3959473 0.84 MAPT (0.69) SMN1; SMN2NPC1RAB9ATTRMAPT
SCHEMBL29551111 0.83 MAPT (0.60) SMN1; SMN2NPC1RAB9ATTRMAPT
SCHEMBL497339 0.83 MAPT (0.60) SMN1; SMN2NPC1RAB9ATTRMAPT
SCHEMBL20746507 0.83 SMN1; SMN2 (0.49) SMN1; SMN2NPC1RAB9ATTRMAPT
SCHEMBL11107245 0.83 TTR (0.54) SMN1; SMN2NPC1RAB9ATTRMAPT
SCHEMBL11101186 0.82 TTR (0.72) SMN1; SMN2NPC1RAB9ATTRMAPT
SCHEMBL28650516 0.82 MAPK1 (0.47) SMN1; SMN2NPC1RAB9ATTRMAPT
SCHEMBL27916746 0.82 MAPT (0.57) SMN1; SMN2NPC1RAB9ATTRMAPT
SCHEMBL8386529 0.79 SMN1; SMN2 (0.58) SMN1; SMN2NPC1RAB9ATTRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230320940-A1 PHOTOCATIONICALLY CURABLE COMPOSITION AND DENTAL CURABLE COMPOSITION TOKUYAMA DENTAL CORPORATION (JP) 2023-10-12 US disclosed
EP-4194477-A1 PHOTOCATIONIC CURABLE COMPOSITION AND CURABLE DENTAL COMPOSITION Tokuyama Dental Corporation (JP) 2023-06-14 EP disclosed
EP-1591098-B1 Cationically curable composition for dental use TOKUYAMA CORP (JP) 2008-08-13 EP disclosed
US-7365106-B2 Cationically curable composition for dental use TOKUYAMA CORPORATION (JP) 2008-04-29 US disclosed
EP-1431315-B1 Photopolymerization initiator and photopolymerizable composition TOKUYAMA CORP (JP) 2007-10-17 EP disclosed
CN-1732883-A Cationically curable composition for dental use TOKUYAMA CORP (JP) 2006-02-15 CN disclosed
US-20050250868-A1 Cationically curable composition for dental use TOKUYAMA CORPORATION (JP) 2005-11-10 US disclosed
EP-1591098-A1 Cationically curable composition for dental use TOKUYAMA CORPORATION (JP) 2005-11-02 EP disclosed
US-20040186195-A1 Photopolymerization initiator and photopolymerizable composition TOKUYAMA CORPORATION (JP) 2004-09-23 US disclosed
EP-1431315-A2 Photopolymerization initiator and photopolymerizable composition Tokuyama Corporation (JP) 2004-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230320940-A1 PHOTOCATIONICALLY CURABLE COMPOSITION AND DENTAL CURABLE COMPOSITION CTH, GCLC, AAAS SMN1; SMN2 3290/4885NPC1 4742/4885RAB9A 2337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.